ClinicalTrials.gg
CompletedNCT00610155Updated Jan 22, 2021Results posted

A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients

An interventional study of Placebo and Pregabalin in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
48th of 55
18 · median 64
Started
2008
with 6 others
No phase
14 of 55
4 open now
Registered
8th of 55
by date
Lead sponsor
9 of 55
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 55 studies testing pregabalin in Pain, this one is the 48th largest by enrollment, is one of 7 that started in 2008, is one of 14 with no phase, and was the 8th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of pregabalin and tramadol SR in a cross-over clinical study design.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of neuropathic pain associated with brush allodynia in specific dermatomes.
  • Brush allodynia score of ≥4 and calculated average pain score of ≥3 on an 11-point numerical rating scale by the completion of down-titration of existing medications.
  • Right-handed

Exclusion criteria

Exclusion Criteria:

  • Subjects with trigeminal neuralgia, central pain (due to cerebrovascular lesions, multiple sclerosis and/or traumatic spinal cord injuries including spinal surgery).
  • Phantom limb pain, painful diabetic neuropathy.
  • Subjects with any other co-existing pain which he/she or a qualified pain physician cannot differentiate from NeP of peripheral origin.
  • Subjects with diabetes mellitus and with an value of >10% upon measurement at screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Placebo comparator
    1

    Drug: Placebo

  • Experimental
    2

    Drug: Pregabalin

  • Experimental
    3

    Drug: Tramadol SR

Interventions

  • DrugPlacebo

    BID

  • Dose 75 mg titrated to 150 mg, bid

  • Dose 50mg titrated to 200 mg, bid

06

What researchers measure

Primary outcomes

  1. Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals Across the Whole Brain

    BOLD brain activation signals in whole brain was assessed using Contrast Parameter Estimates (COPE) images in response to dynamic mechanical allodynia of the affected side (DMAa), dynamic mechanical allodynia of the control side (DMAc), thermal pain (TH) and checkerboard visual stimuli (VIS).

    Time frame: Day 8, 22, 36

  2. Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Affected Side (DMAa)

    BOLD brain activation signals in pre-defined region of interest(ROI):anterior cingulate cortex(ACC);left,right anterior cortex(\[AIC_L \],\[AIC_R\]);left,right mid-insular cortex(\[MIC_L\],\[MIC_R\]);left,right posterior insular cortex(\[PIC_L\],\[PIC_R\]);left,right amygdala(\[Amyg_L\],\[Amyg_R\]);primary,secondary somatosensory cortex(\[S1\],\[S2\]);sensory part of thalamus(SensTHAL);midbrain reticular formation(MRF);nucleus cuneiformis(NucCun);periaqueductal gray(PAG). Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis,signal change is unit less measure but approximated to percent signal change by grand scaling(effects divided by 10000 to get percent signal change).

    Time frame: Day 8, 22, 36

  3. Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Control Side (DMAc)

    BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).

    Time frame: Day 8, 22, 36

  4. Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Thermal Stimulation (TH)

    BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).

    Time frame: Day 8, 22, 36

  5. Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Visual Stimulation (VIS)

    BOLD brain activation signals in pre-defined ROI in response to checkerboard visual stimuli (flashing at 2 Hz). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only.

    Time frame: Day 8, 22, 36

  6. Arterial Spin Labelling (ASL) Using fMRI of Brain Activation Signals Across the Whole Brain and in Defined Brain Regions

    Continuous ASL sequence fMRI imaging modality assessing brain activation signals across the whole brain and in defined ROI to assess effects of evoked pain along with changes in regional cerebral blood flow (rCBF). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG.

    Time frame: Day 8, 22, 36

Secondary outcomes

  1. 36-Item Short-Form Health Survey (SF-36)

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Time frame: Day 8, 22, 36

  2. Beck Depression Inventory (BDI)

    BDI is a 21 item participant rated inventory evaluating depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicate more depression.

    Time frame: Day 8, 22, 36

  3. State and Trait Anxiety Questionnaire

    Self-report scale completed by the participant. Separate scales measure state (20 items) and trait (20 items) anxiety. The participant report how they feel "right now at this moment" for state anxiety and how they "generally" feel for trait anxiety. The "state" items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very much so). The "trait" items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). Scores range from 20-80 for each scale. Higher scores indicate more impaired participants.

    Time frame: Day 8, 22, 36

  4. Pain Catastrophising Scale (PCS)

    The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores indicate greater extent of pain catastrophizing.

    Time frame: Day 8, 22, 36

  5. Neuropathic Pain Symptom Inventory (NPSI)

    NPSI: participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicate a greater intensity of pain.

    Time frame: Baseline (Day -7), Day 8, 22, 36

  6. Daily Pain Score

    Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning using 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). The daily pain scores for an average of the last 7 days and an average of last 3 days were calculated.

    Time frame: Day -35 through Day 36

  7. Present Pain Intensity Score (PPIS)

    Participants answered: "Please rate your pain from 0-10 that best describes the intensity of pain right now". PPIS assessed on 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

    Time frame: Day 8, 22, 36

  8. Doleur Neuropathic 4 (DN4) Score

    DN4 questionnaire provides a simple diagnosis of Neuropathic pain (NeP) by asking for yes/no answers to 4 questions (10 sub questions in total). Each question was scored on a scale of 0 (No) and 1 (Yes). Total score was calculated as sum of the 10 individual questions. Total score range 0-10, higher score indicated more neuropathic pain.

    Time frame: Day -35

07

Results

Posted Nov 28, 2013
Limitations and caveats
Results for primary outcome, BOLD activation signals(whole brain) was not available to reported, as DMAa, DMAc, TH and VIS were captured as COPE images only, which could not be included in basic results format.

Participant flow

Period 1
Participant flow — Period 1
MilestonePregabalin Then Tramadol Then PlaceboTramadol Then Placebo Then PregabalinPlacebo Then Pregabalin Then TramadolPregabalin Then Placebo Then TramadolPlacebo Then Tramadol Then PregabalinTramadol Then Pregabalin Then Placebo
Started434331
Completed433331
Not completed001000
Withdrew: Withdrawal by subject001000
Washout Period 1 (7 Days)
Participant flow — Washout Period 1 (7 Days)
MilestonePregabalin Then Tramadol Then PlaceboTramadol Then Placebo Then PregabalinPlacebo Then Pregabalin Then TramadolPregabalin Then Placebo Then TramadolPlacebo Then Tramadol Then PregabalinTramadol Then Pregabalin Then Placebo
Started433331
Completed433331
Not completed000000
Period 2
Participant flow — Period 2
MilestonePregabalin Then Tramadol Then PlaceboTramadol Then Placebo Then PregabalinPlacebo Then Pregabalin Then TramadolPregabalin Then Placebo Then TramadolPlacebo Then Tramadol Then PregabalinTramadol Then Pregabalin Then Placebo
Started433331
Completed433331
Not completed000000
Washout Period 2 (7 Days)
Participant flow — Washout Period 2 (7 Days)
MilestonePregabalin Then Tramadol Then PlaceboTramadol Then Placebo Then PregabalinPlacebo Then Pregabalin Then TramadolPregabalin Then Placebo Then TramadolPlacebo Then Tramadol Then PregabalinTramadol Then Pregabalin Then Placebo
Started433331
Completed433331
Not completed000000
Period 3
Participant flow — Period 3
MilestonePregabalin Then Tramadol Then PlaceboTramadol Then Placebo Then PregabalinPlacebo Then Pregabalin Then TramadolPregabalin Then Placebo Then TramadolPlacebo Then Tramadol Then PregabalinTramadol Then Pregabalin Then Placebo
Started433331
Completed333331
Not completed100000
Withdrew: Adverse event100000

Outcome measures

PrimaryVoxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals Across the Whole Brain

BOLD brain activation signals in whole brain was assessed using Contrast Parameter Estimates (COPE) images in response to dynamic mechanical allodynia of the affected side (DMAa), dynamic mechanical allodynia of the control side (DMAc), thermal pain (TH) and checkerboard visual stimuli (VIS).

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

PrimaryVoxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Affected Side (DMAa)

BOLD brain activation signals in pre-defined region of interest(ROI):anterior cingulate cortex(ACC);left,right anterior cortex(\[AIC_L \],\[AIC_R\]);left,right mid-insular cortex(\[MIC_L\],\[MIC_R\]);left,right posterior insular cortex(\[PIC_L\],\[PIC_R\]);left,right amygdala(\[Amyg_L\],\[Amyg_R\]);primary,secondary somatosensory cortex(\[S1\],\[S2\]);sensory part of thalamus(SensTHAL);midbrain reticular formation(MRF);nucleus cuneiformis(NucCun);periaqueductal gray(PAG). Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis,signal change is unit less measure but approximated to percent signal change by grand scaling(effects divided by 10000 to get percent signal change).

Time frame:
Day 8, 22, 36
Reported as:
Least squares mean · percent signal change
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Affected Side (DMAa)
percent signal changePregabalinTramadolPlacebo
ACC-17.3 ± 9.718.6 ± 9.77.4 ± 9.7
AIC_L8.1 ± 8.823.3 ± 8.830.8 ± 8.8
AIC_R11.1 ± 10.021.9 ± 10.017.1 ± 10.0
MIC_L3.8 ± 8.423.4 ± 8.430.0 ± 8.4
MIC_R8.6 ± 8.413.4 ± 8.418.3 ± 8.4
PIC_L-6.8 ± 5.2-5.8 ± 5.2-0.3 ± 5.2
PIC_R-13.6 ± 8.52.9 ± 8.56.5 ± 8.5
Amyg_L-5.7 ± 10.25.5 ± 10.28.5 ± 10.2
Amyg_R-1.4 ± 8.520.3 ± 8.521.7 ± 8.5
S1-28.5 ± 20.5-4.1 ± 20.5-2.9 ± 20.5
S22.5 ± 10.8-3.2 ± 10.810.8 ± 10.8
SensTHAL8.0 ± 5.416.5 ± 5.49.6 ± 5.4
MRF7.0 ± 5.06.4 ± 5.011.7 ± 5.0
NucCun1.1 ± 5.5-0.9 ± 5.512.9 ± 5.5
PAG-3.8 ± 7.9-15.3 ± 7.92.5 ± 7.9
PrimaryVoxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Control Side (DMAc)

BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).

Time frame:
Day 8, 22, 36
Reported as:
Least squares mean · percent signal change
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Dynamic Mechanical Allodynia of the Control Side (DMAc)
percent signal changePregabalinTramadolPlacebo
ACC-22.3 ± 12.0-3.7 ± 12.00.2 ± 12.0
AIC_L-13.5 ± 8.018.2 ± 8.020.2 ± 8.0
AIC_R-10.6 ± 7.410.3 ± 7.420.2 ± 7.4
MIC_L-7.6 ± 8.49.7 ± 8.49.0 ± 8.4
MIC_R-9.2 ± 6.22.8 ± 6.20.7 ± 6.2
PIC_L-14.9 ± 6.9-8.1 ± 6.90.8 ± 6.9
PIC_R-17.2 ± 9.42.4 ± 9.46.3 ± 9.4
Amyg_L-14.3 ± 7.31.5 ± 7.3-3.4 ± 7.3
Amyg_R-10.3 ± 9.72.0 ± 9.7-3.8 ± 9.7
S1-31.6 ± 16.2-4.5 ± 16.214.6 ± 16.2
S2-0.4 ± 8.39.6 ± 8.313.5 ± 8.3
SensTHAL3.9 ± 5.3-2.8 ± 5.36.7 ± 5.3
MRF1.5 ± 4.6-6.6 ± 4.6-1.7 ± 4.6
NucCun1.0 ± 4.9-8.2 ± 4.9-1.8 ± 4.9
PAG1.6 ± 7.8-12.0 ± 7.8-5.0 ± 7.8
PrimaryVoxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Thermal Stimulation (TH)

BOLD brain activation signals in pre-defined ROI. ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only. In voxel BOLD analysis, signal change is unit less measure but is approximated to percent signal change here by grand scaling (dividing effects by 10000 to get percent signal change).

Time frame:
Day 8, 22, 36
Reported as:
Least squares mean · percent signal change
Voxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Thermal Stimulation (TH)
percent signal changePregabalinTramadolPlacebo
ACC102.2 ± 25.992.5 ± 25.883.3 ± 25.8
AIC_L92.1 ± 21.9103.4 ± 21.8118.7 ± 21.8
AIC_R121.7 ± 20.7104.6 ± 20.6104.0 ± 20.6
MIC_L93.4 ± 19.6105.2 ± 19.5100.4 ± 19.5
MIC_R106.6 ± 17.371.1 ± 17.392.0 ± 17.3
PIC_L31.2 ± 16.044.6 ± 15.934.2 ± 15.9
PIC_R75.3 ± 20.195.5 ± 20.091.8 ± 20.0
Amyg_L29.7 ± 16.524.9 ± 16.536.4 ± 16.5
Amyg_R77.5 ± 22.557.2 ± 22.567.0 ± 22.5
S1-49.0 ± 30.237.7 ± 30.127.7 ± 30.1
S273.6 ± 21.294.6 ± 21.274.5 ± 21.2
SensTHAL19.4 ± 12.10.8 ± 12.110.4 ± 12.1
MRF34.3 ± 14.725.5 ± 14.637.7 ± 14.6
NucCun38.7 ± 11.527.7 ± 11.540.5 ± 11.5
PAG63.3 ± 15.953.6 ± 15.844.6 ± 15.8
PrimaryVoxel-wise Blood Oxygen Level Dependent (BOLD) Using fMRI of Brain Activation Signals in Defined Brain Regions in Response to Visual Stimulation (VIS)

BOLD brain activation signals in pre-defined ROI in response to checkerboard visual stimuli (flashing at 2 Hz). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG. Prior to ROI analysis, a prelimanary anlysis was performed, wherein it was concluded that ROI analysis was to be carried out for DMAa, DMAc amd TH only.

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

PrimaryArterial Spin Labelling (ASL) Using fMRI of Brain Activation Signals Across the Whole Brain and in Defined Brain Regions

Continuous ASL sequence fMRI imaging modality assessing brain activation signals across the whole brain and in defined ROI to assess effects of evoked pain along with changes in regional cerebral blood flow (rCBF). ROI were ACC; AIC_L; AIC_R; MIC_L; MIC_R; PIC_L; PIC_R; Amyg_L; Amyg_R; S1; S2; SensTHAL; MRF; NucCun; PAG.

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

Secondary36-Item Short-Form Health Survey (SF-36)

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

SecondaryBeck Depression Inventory (BDI)

BDI is a 21 item participant rated inventory evaluating depression symptoms, cognition, and physical symptoms of fatigue, weight loss, lack of interest in sex. Individual items are scored on a 4 point scale (0 to 3), with 0=none/absent and 3=most severe. Total score: 0 to 63; higher score indicate more depression.

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

SecondaryState and Trait Anxiety Questionnaire

Self-report scale completed by the participant. Separate scales measure state (20 items) and trait (20 items) anxiety. The participant report how they feel "right now at this moment" for state anxiety and how they "generally" feel for trait anxiety. The "state" items are scored as: 1 (not at all), 2 (somewhat true), 3 (moderately true), 4 (very much so). The "trait" items are scored as: 1 (almost never), 2 (sometimes), 3 (often), 4 (almost always). Scores range from 20-80 for each scale. Higher scores indicate more impaired participants.

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

SecondaryPain Catastrophising Scale (PCS)

The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores indicate greater extent of pain catastrophizing.

Time frame:
Day 8, 22, 36

No measurements were reported for this outcome.

SecondaryNeuropathic Pain Symptom Inventory (NPSI)

NPSI: participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicate a greater intensity of pain.

Time frame:
Baseline (Day -7), Day 8, 22, 36

No measurements were reported for this outcome.

SecondaryDaily Pain Score

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning using 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). The daily pain scores for an average of the last 7 days and an average of last 3 days were calculated.

Time frame:
Day -35 through Day 36
Reported as:
Least squares mean · units on a scale
Daily Pain Score
units on a scalePregabalinTramadolPlacebo
Last 7 days5.57 ± 0.3715.28 ± 0.3706.40 ± 0.370
Last 3 days5.46 ± 0.4665.10 ± 0.4546.33 ± 0.454
SecondaryPresent Pain Intensity Score (PPIS)

Participants answered: "Please rate your pain from 0-10 that best describes the intensity of pain right now". PPIS assessed on 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

Time frame:
Day 8, 22, 36
Reported as:
Least squares mean · units on a scale
Present Pain Intensity Score (PPIS)
units on a scalePregabalinTramadolPlacebo
Present Pain Intensity Score (PPIS)5.54 ± 0.5524.13 ± 0.5515.83 ± 0.551
SecondaryDoleur Neuropathic 4 (DN4) Score

DN4 questionnaire provides a simple diagnosis of Neuropathic pain (NeP) by asking for yes/no answers to 4 questions (10 sub questions in total). Each question was scored on a scale of 0 (No) and 1 (Yes). Total score was calculated as sum of the 10 individual questions. Total score range 0-10, higher score indicated more neuropathic pain.

Time frame:
Day -35

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/17 (0%)14/17 (82.4%)
Tramadol—0/17 (0%)14/17 (82.4%)
Placebo—0/18 (0%)11/18 (61.1%)
Most frequent other events
Showing 10 of 49
Most frequent other events
EventPregabalinTramadolPlacebo
NauseaGastrointestinal disorders1/178/171/18
DizzinessNervous system disorders7/178/172/18
FatigueGeneral disorders3/176/171/18
PruritusSkin and subcutaneous tissue disorders0/175/170/18
ConstipationGastrointestinal disorders0/174/170/18
VomitingGastrointestinal disorders0/174/170/18
SomnolenceNervous system disorders2/174/171/18
Dry mouthGastrointestinal disorders3/170/171/18
NasopharyngitisInfections and infestations3/170/171/18
Decreased appetiteMetabolism and nutrition disorders0/173/170/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean44.7 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female12
Male6
08

Study locations

2 sites
  • Pfizer Investigational Site
    Portsmouth, Hampshire PO3 6AD, United Kingdom
  • Pfizer Investigational Site
    Solihull, West Midlands B91 2JL, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2008
First posted
Feb 7, 2008
Start
Sep 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Nov 28, 2013
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00610155
Responsible party
Sponsor
First posted
Feb 7, 2008
Start date
Sep 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Nov 28, 2013
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Tramadol

Start the discussion